Nongoitrous (Type I) Amiodarone-Associated Thyrotoxicosis: Evidence of Follicular Disruption In Vitro and In Vivo
Abstract
Treatment with the antiarrhythmic agent amiodarone results in alterations in thyroid hormone metabolism, and can induce either hypothyroidism or hyperthyroidism (amiodarone-associated thyrotoxicosis, AAT). AAT occurs in patients both with and without preexisting goiter. In our study of the nongoitrous variety, the effect in vitro of amiodarone treatment and of concurrent treatment with potential inhibitors on thyroid cells (FRTL-5) was assessed by measuring the release of radiolabeled chromium (51Cr). In addition, thyroid histopathology was evaluated in autopsy specimens from six amiodarone-treated patients who had no pretreatment evidence of thyroid disease. Histopathologic examination revealed minimal or no evidence of thyroid follicular damage in specimens from amiodarone-treated euthyroid patients (n = 4). In contrast, moderate to severe follicular damage and disruption were present in glands from patients with AAT (n = 2). Studies in vitro showed amiodarone to be cytotoxic to thyroid cells; this effect was inhibited by treatment with dexamethasone (10(-3) mmol) or perchlorate (2.5 micrograms/mL). In summary, we demonstrate evidence in vitro and in vivo of amiodarone-induced thyroid follicular damage and disruption in specimens from patients with nongoitrous AAT and in cultured normal thyroid cells. In addition, we demonstrate inhibition of this effect following treatment in vitro with dexamethasone or perchlorate. Our findings support the concept that nongoitrous (type I) AAT results from direct drug toxicity with disruption of thyroid follicles and subsequent release of preformed thyroid hormone.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Two distinct mechanisms have been proposed in the development of AIT: an iodine-induced form of hyperthyroidism (type 1 AIT) due to the high iodine content of amiodarone (37% by molecular weight) and a destructive thyroiditis (type 2 AIT) due to direct toxicity of amiodarone on follicular cells.
“Two distinct mechanisms have been proposed in the development of AIT, including an iodine-induced form of hyperthyroidism (type 1 AIT) due to the high iodine content of amiodarone (37% by molecular weight) and a destructive thyroiditis (type 2 AIT) due to direct toxicity of amiodarone on follicular cells.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [579]
Type 1 AIT tends to occur in patients with underlying thyroid autonomy in a nodular goiter or GD, whereas type 2 AIT occurs as a result of direct damage or induction of apoptosis in thyrocytes by amiodarone.
“Type 1 AIT tends to occur in patients with underlying thyroid autonomy in a nodular goiter, or GD, whereas type 2 AIT occurs as a result of direct damage or induction of apoptosis in thyrocytes by amiodarone (579-582).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [579]
Cites
Environmental Iodine Intake and Thyroid Dysfunction During Chronic Amiodarone Therapy
Martino, E., SAFRAN, M., AGHINI-LOMBARDI, F., RAJATANAVIN, R., LENZIARDI, M., FAY, M., PACCHIAROTTI, A., ARONIN, N., MACCHIA, E., HAFFAJEE, C., et al. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-1-28 · Cited by 370 · see citing works
Burger, A., Dinichert, D., NICOD, P. H., Jenny, M., Lemarchand-Béraud, T., & Vallotton, M. B. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108466 · Cited by 311 · see citing works
Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism
Trip, M. D., Wiersinga, W. M., & Plomp, T. A. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90187-3 · Cited by 269 · see citing works
Iodide-Induced Thyrotoxicosis in Boston
Vagenakis, A. G., Wang, C.-A., Burger, A., Maloof, F., Braverman, L. E., & Ingbar, S. H. (1972) · New England Journal of Medicine · doi:10.1056/nejm197209142871101 · Cited by 186 · see citing works
Serum interleukin-6 in amiodarone-induced thyrotoxicosis
Bartalena, L., Grasso, L., Brogioni, S., Aghini-Lombardi, F., Braverman, L. E., & Martino, E. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.2.8106631 · Cited by 172 · see citing works
Martino, E., Aghini-Lombardi, F., Mariotti, S., Lenziardi, M., Baschieri, L., Braverman, L. E., & Pinchera, A. (1986) · Journal of Endocrinological Investigation · doi:10.1007/bf03348098 · Cited by 149 · see citing works
Pathology of the Thyroid in Amiodarone-Associated Thyrotoxicosis
Smyrk, T. C., Goellner, J. R., BRENNAN, M. D., & Carney, J. A. (1987) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198703000-00004 · Cited by 127 · see citing works
Self-citationAMIODARONE IODINE‐INDUCED HYPOTHYROIDISM: RISK FACTORS AND FOLLOW‐UP IN 28 CASES
Martino, E., Aghini-Lombardi, F., Mariotti, S., Bartalena, L., Lenziardi, M., Ceccarelli, C., Bambini, G., Safran, M., Braverman, L. E., & Pinchera, A. (1987) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1987.tb00781.x · Cited by 119 · see citing works
Iodine Kinetic Studies during Amiodarone Treatment*
Rao, R. H., McCREADY, V. R., & Spathis, G. S. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-3-563 · Cited by 114 · see citing works
Iodine‐induced thyrotoxicosis: analysis of eighty‐five consecutive cases
Léger, A., MASSIN, J. P., Laurent, M. F., Vincens, M., Auriol, M., Helal, O. B., Chomette, G., & Savoie, J. C. (1984) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1984.tb01212.x · Cited by 109 · see citing works
Amiodarone: A Common Source of Iodine-Induced Thyrotoxicosis
Martino, E., Aghini-Lombardi, F., Mariotti, S., Bartalena, L., Braverman, L. E., & Pinchera, A. (2008) · Hormone Research · doi:10.1159/000180696 · Cited by 108 · see citing works
Studies on the in vitro cytotoxic effect of amiodarone.
Chiovato, L., Martino, E., Tonacchera, M., Santini, F., Lapi, P., Mammoli, C., Braverman, L. E., & Pinchera, A. (1994) · Endocrinology · doi:10.1210/endo.134.5.8156930 · Cited by 107 · see citing works
Roti, E. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.7.886 · Cited by 78 · see citing works
Bahn, R. S., Gorman, C. A., JOHNSON, C. M., & Smith, T. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-622 · Cited by 66 · see citing works
Self-citationCytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes
Beddows, S. A., Page, S. R., Taylor, A. H., McNerney, R., Whitley, G. S. J., Johnstone, A. P., & Nussey, S. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90648-5 · Cited by 61 · see citing works
Prednisone in amiodarone-induced thyrotoxicosis.
Wimpfheimer, C., Stäubli, M., Schädelin, J., & Studer, H. (1982) · BMJ · doi:10.1136/bmj.284.6332.1835-a · Cited by 54 · see citing works
Newnham, H. H., Topliss, D. J., GRAND, B. A. L., et al. (1988) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1988.tb02237.x · Cited by 52 · see citing works
Roti, E., Minelli, R., Gardini, E., Bianconi, L., Gavaruzzi, G., Ugolotti, G., Neri, T. M., & Braverman, L. E. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.5.1331165 · Cited by 52 · see citing works
Amiodarone-induced pulmonary toxicity in rats: Biochemical and pharmacological characteristics
Reasor, M. J., Ogle, C. L., & Kacew, S. (1989) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(89)90061-6 · Cited by 47 · see citing works
Amiodarone and Desethylamiodarone Toxicity in Isolated Hepatocytes in Culture
Gross, S. A., Bandyopadhyay, S., Klaunig, J. E., et al. (1989) · Experimental Biology and Medicine · doi:10.3181/00379727-190-42844 · Cited by 38 · see citing works
PARIS, J., McConahey, W. M., Owen, C. A., et al. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-1-57 · Cited by 38 · see citing works
Powis, G., OLSEN, R. A., Standing, J. E., et al. (1990) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(90)90271-u · Cited by 30 · see citing works
Amiodarone and thyroid autoimmunity in the United Kingdom.
Weetman, A. P., Bhandal, S., Burrin, J. M., et al. (1988) · BMJ · doi:10.1136/bmj.297.6640.33 · Cited by 29 · see citing works
Kachel, D. L., Moyer, T. P., & Martin, W. J. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12719-5 · Cited by 29 · see citing works
Amiodarone-induced thyrotoxicosis suggestive of thyroid damage
Lambert, M., Unger, J., Nayer, P. D., Brohet, C., & Gangji, D. (1990) · Journal of Endocrinological Investigation · doi:10.1007/bf03348618 · Cited by 26 · see citing works
Thyroidectomy for amiodarone-induced thyrotoxicosis
Farwell, A. P. (1990) · JAMA · doi:10.1001/jama.263.11.1526 · Cited by 25 · see citing works
Amiodarone-induced thyroiditis
Leung, W., Pun, K.-K., Lau, C., et al. (1989) · American Heart Journal · doi:10.1016/0002-8703(89)90602-9 · Cited by 15 · see citing works
Amiodarone Pulmonary Toxicity: Morphologic and Biochemical Features
Reasor, M. J., & Kacew, S. (1991) · Experimental Biology and Medicine · doi:10.3181/00379727-196-43158a · Cited by 15 · see citing works
Massart, C., Hody, B., Condé, D., et al. (1989) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(89)90119-6 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938 · see citing works
Surgical Management of Amiodarone‐associated Thyrotoxicosis: Mayo Clinic Experience
Houghton, S. G., Farley, D. R., Brennan, M. D., van Heerden, J. A., Thompson, G. B., & Grant, C. S. (2004) · World Journal of Surgery · doi:10.1007/s00268-004-7599-6 · Cited by 103 · see citing works
Self-citationTreatment of Amiodarone-Induced Thyrotoxicosis Type 2: A Randomized Clinical Trial
Eskes, S. A., Endert, E., Fliers, E., Geskus, R. B., Dullaart, R. P. F., Links, T. P., & Wiersinga, W. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2390 · Cited by 78 · see citing works
Loy, M., Perra, E., Melis, A., Cianchetti, M. E., Piga, M., Serra, A., Pinna, G., & Mariotti, S. (2007) · Acta Radiologica · doi:10.1080/02841850701342138 · Cited by 55 · see citing works
- Authors
- BRENNAN, M. D., ERICKSON, D. Z., CARNEY, J. A., & BAHN, R. S.
- Affiliations
- Mayo Clinic (US)
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 1995-06
- Volume
- 5
- Issue
- 3
- Pages
- 177-183
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W1535986052
- Cited by
- 61
- References
- 29
- Citations by year
- 2022: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 5
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Thyroid (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- amiodarone, FRTL-5 cells, dexamethasone, perchlorate, thyroid hormone secretion, thyroid histopathology
- MeSH terms
- Adult, Aged, Amiodarone, Cell Line, Chromium Radioisotopes, Cytotoxins, Dexamethasone, Female, Glucocorticoids, Humans, Hyperthyroidism, Male, Middle Aged, Perchlorates, Thyroid Gland, Thyrotoxicosis, Survival Analysis, Sodium Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review